

II. *Public Meeting*: NIOSH will hold a public meeting to allow for comments on future directions for surveillance of injuries within the agricultural production industry. The meeting is open to the public, limited only by the capacity of 100 connections to the Web based conference.

Confirm your attendance to this meeting by sending an email to [mgoldcamp@cdc.gov](mailto:mgoldcamp@cdc.gov) by March 16, 2015. An email confirming registration will be sent from NIOSH and will include details needed to participate.

Requests to make presentations at the public meeting should be emailed to [mgoldcamp@cdc.gov](mailto:mgoldcamp@cdc.gov) by March 16, 2015. All requests to present should contain the name, address, telephone number, and relevant business affiliations of the presenter. Presenters will be assigned a 10-minute slot on the agenda. Presenters who wish to use slides must email an electronic file in Microsoft PowerPoint format to [mgoldcamp@cdc.gov](mailto:mgoldcamp@cdc.gov) by March 16, 2015. An email confirming the presentation request will be sent from NIOSH and will include details needed to present and an approximate start time for the presentation.

If a presenter is not in attendance when his/her presentation is scheduled to begin, the remaining presenters will be heard in order. After the last scheduled presenter is heard, those who missed their opportunity may be allowed to present, limited by time available.

Attendees who wish to speak, but did not submit a request for the opportunity to make a presentation, may be given this opportunity after the scheduled presenters are heard, at the discretion of

the presiding officer and limited by time available.

The public meeting, including all presentations and slides, will be recorded, transcribed, and posted without change to <http://www.regulations.gov>, including any personal information provided.

III. *Written Comments*: You may submit comments, identified by CDC–2015–0005 and Docket Number NIOSH–281, by either of the following methods:

- *Federal eRulemaking Portal*: <http://www.regulations.gov> Follow the instructions for submitting comments.

- *Mail*: National Institute for Occupational Safety and Health, NIOSH Docket Office, 1090 Tusculum Avenue MS C–34, Cincinnati, Ohio 45226–1998.

All information received in response to this notice must include the agency name and docket number [CDC–2015–0005; NIOSH–281]. All relevant comments received will be posted without change to <http://www.regulations.gov>, including any personal information provided. All electronic comments should be formatted as Microsoft Word. All information received in response to this notice will also be available for public examination and copying at the NIOSH Docket Office, 1150 Tusculum Avenue, Room 155, Cincinnati, Ohio 45226–1998.

Dated: February 18, 2015.

**John Howard,**

*Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.*

[FR Doc. 2015–03949 Filed 2–25–15; 8:45 am]

**BILLING CODE 4163–19–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Administration for Children and Families**

**Proposed Information Collection Activity; Comment Request**

*Title*: Youth Education and Relationship Services (YEARS) Descriptive Study.

*OMB No.*: New Collection.

*Description*: Since 2006, Congress has authorized dedicated funding (currently at the level of \$75 million annually) to support programs promoting healthy marriage and relationship education (HMRE). In order to better understand the services that federally-funded HMRE programs are providing to youth and the populations the programs are reaching, The Office of Planning, Research and Evaluation (OPRE), within ACF/HHS is proposing data collection activity as part of the Youth Education and Relationship Services (YEARS) Descriptive Study. The data that ACF proposes to collect includes information on funding spent serving youth, the number of youth being served, youth demographic characteristics, characteristics of the organizations or programs serving youth, information on program curricula and contents, and program implementation information. This data is to be collected through a web-based survey that is to be completed by HMRE grantee program staff. This information will be critical to informing future efforts to improve HMRE programs serving youth.

*Respondents*: Healthy marriage and relationship education (HMRE) grantee program staff.

**ANNUAL BURDEN ESTIMATES**

Instrument	Total number of respondents	Annual number of respondents	Number of responses per respondent	Average burden hours per response	Annual burden hours
Web-based survey .....	176	88	1	0.5	44

*Estimated Total Annual Burden Hours: 44*

In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Planning, Research

and Evaluation, 370 L’Enfant Promenade SW., Washington, DC 20447, Attn: OPRE Reports Clearance Officer. Email address: [OPREinfocollection@acf.hhs.gov](mailto:OPREinfocollection@acf.hhs.gov). All requests should be identified by the title of the information collection. The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the

proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

**Reference**

[1] [http://www.ssa.gov/OP\\_Home/ssact/](http://www.ssa.gov/OP_Home/ssact/)

*title04/0403.htm.*

**Karl Koerper,**

*Reports Clearance Officer.*

[FR Doc. 2015-03924 Filed 2-25-15; 8:45 am]

**BILLING CODE 4184-73-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-20115-N-0456]

#### Pediatric Stakeholder Meeting; Request for Comments

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of public meeting; request for comments.

**SUMMARY:** The Food and Drug Administration's (FDA) Office of Pediatric Therapeutics (OPT), the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) are announcing a public meeting seeking input from patient groups, consumer groups, regulated industry, academia and other interested parties to obtain any recommendations or information relevant to the report to Congress that FDA is required to submit concerning pediatrics, as outlined in section 508 of the Food and Drug Administration Safety and Innovation Act (FDASIA) (see the **SUPPLEMENTARY INFORMATION** section for additional background information).

**DATES:** The public meeting will be held on March 25, 2015, from 9 a.m. to 5 p.m. Registration to attend the meeting should be received by March 20, 2015 (see the **SUPPLEMENTARY INFORMATION** section for instructions).

**ADDRESSES:** The meeting will be held at FDA's White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (1503-B & C), Silver Spring, MD 20993-0002. Entrance for the public meeting participants (non-FDA employees) is through Building 1 where routine security check procedures will be performed. For information on parking and security procedures, please refer to <http://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740>.

Submit either electronic or written comments by April 24, 2015. Submit electronic comments to <http://www.regulations.gov>. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm.

1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.

FDA will post the agenda approximately 5 days before the meeting at: <http://www.fda.gov/NewsEvents/MeetingsConferencesWorkshops/ucm433552.htm>.

#### FOR FURTHER INFORMATION CONTACT:

Terrie L. Crescenzi, Office of Pediatric Therapeutics, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, [terrie.crescenzi@fda.hhs.gov](mailto:terrie.crescenzi@fda.hhs.gov) or Betsy Sanford, Office of Pediatric Therapeutics, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, [elizabeth.sanford@fda.hhs.gov](mailto:elizabeth.sanford@fda.hhs.gov).

#### SUPPLEMENTARY INFORMATION:

##### I. Background

On July 9, 2012, the President signed into law the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub. L. 112-144). Section 508 of FDASIA directs the Secretary of HHS to submit a report to Congress on the implementation of the Best Pharmaceuticals for Children Act (BPCA) and Pediatric Research Equity Act (PREA). The first report must be submitted to Congress by July 9, 2016, and every 5 years thereafter. FDASIA also requires FDA to obtain, at least 180 days prior to submission of the report, stakeholder input from patient groups, consumer groups, regulated industry, academia, and any other interested parties to obtain any recommendations or information relevant to the report including suggestions for modifications that would improve pediatric drug research and pediatric labeling of drugs and biological products.

The basic content of the report will include: An assessment of the effectiveness of BPCA (section 505A) and PREA (section 505B) in improving information about pediatric uses for approved drugs and biological products, including the number and type of labeling changes made since the enactment of FDASIA and the importance of such uses in the improvement of the health of children; various statistics related to both PREA and BPCA, including the Written Request referral process with the National Institutes of Health; an assessment of the timeliness and effectiveness of pediatric study plans; an assessment of studying biologics; efforts made to increase the number of studies conducted in the neonatal population; the number and importance of drugs and biologics studied in

children with cancer and any recommendations for modification to the programs that would improve pediatric drug research and increase labeling of drugs and biologics; an assessment of the successes of and limitations to studying drugs for rare diseases; an assessment of the efforts to address the suggestions and options described in any prior report issued by the Comptroller General, Institute of Medicine, or the Secretary, and any stakeholder recommendations or modifications that would improve pediatric drug research and pediatric labeling of drugs and biological products.

The specific topics to be discussed at the meeting will include, but not be limited to, pediatric labeling changes, waivers and deferrals, Written Requests, pediatric study plans, programmatic activities with the NIH Written Request referral process, activities concerning neonates, pediatric cancers and rare diseases, and transparency.

##### II. Meeting Attendance and Participation

If you wish to attend this meeting, visit <http://stakeholderinput.eventbrite.com>. Please register by March 20, 2015. Those who are unable to attend the meeting in person can register to view a live Webcast of the meeting. You will be asked to indicate in your registration if you plan to attend in person or via the Webcast. Your registration will also contain your complete contact information, including name, title, affiliation, address, email address, and phone number. Seating will be limited so early registration is recommended. Registration is free and will be on a first-come, first-served basis. Onsite registration on the day of the meeting will be based on space availability. If you need special accommodations due to a disability, please contact Betsy Sanford (see **FOR FURTHER INFORMATION CONTACT**) at least 7 days in advance. Persons attending the meeting are advised that FDA is not responsible for providing access to electrical outlets.

Persons interested in presenting comments at the meeting will be asked to indicate this in their registration. FDA will try to accommodate all participant requests to speak, however the duration of comments may be limited by time constraints.

Comments: Regardless of attendance at the public meeting, you can submit electronic or written comments to the public docket (see **ADDRESSES**) by April 24, 2015. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m.,